- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 27, Issue 42, 2020
Current Medicinal Chemistry - Volume 27, Issue 42, 2020
Volume 27, Issue 42, 2020
-
-
Nitric Oxide and Hydrogen Sulfide: A Nice Pair in the Respiratory System
Authors: Salvatore Fuschillo, Letizia Palomba, Rosanna Capparelli, Andrea Motta and Mauro ManiscalcoNitric Oxide (NO) is internationally regarded as a signal molecule involved in several functions in the respiratory tract under physiological and pathogenic conditions. Hydrogen Sulfide (H2S) has also recently been recognized as a new gasotransmitter with a diverse range of functions similar to those of NO. Depending on their respective concentrations, both these molecules act synergistically or antagonistically as signals or d Read More
-
-
-
Oxidative and Nitrosative Stress in the Pathogenesis of Obstructive Lung Diseases of Increasing Severity
Authors: Antonino Di Stefano, Mauro Maniscalco, Bruno Balbi and Fabio L.M. RicciardoloThe imbalance between increased oxidative agents and antioxidant defence mechanisms is central in the pathogenesis of obstructive lung diseases such as asthma and COPD. In these patients, there are increased levels of reactive oxygen species. Superoxide anions (O2 -), Hydrogen Peroxide (H2O2) and hydroxyl radicals (•OH) are critical for the formation of further cytotoxic radicals in the bronchi and lung parenchyma. Chro Read More
-
-
-
An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma
Authors: Giovanni Rolla, Enrico Heffler, Stefano Pizzimenti, Alain Michils and Andrei MalinovschiAsthma is a heterogeneous disease with regard to the inflammatory pathways activated. In recent years, biologic drugs (monoclonal antibodies) directed towards specific components of type 2 inflammation have been approved for the treatment of severe asthma. Phenotyping of patients with severe asthma and evaluation of biomarkers have been recommended to help identify patients who are candidates for treatment Read More
-
-
-
The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets
Authors: Zsófia Lázár, Martina Meacute;száros and Andras BikovThe altered Nitric Oxide (NO) pathway in the pulmonary endothelium leads to increased vascular smooth muscle tone and vascular remodelling, and thus contributes to the development and progression of pulmonary arterial hypertension (PAH). The pulmonary NO signalling is abrogated by the decreased expression and dysfunction of the endothelial NO synthase (eNOS) and the accumulation of factors blocking eNOS functio Read More
-
-
-
Clinical Values of Nitric Oxide Parameters from the Respiratory System
Authors: Lauri Lehtimäki, Tuomas Karvonen and Marieann HögmanBackground: Fractional exhaled nitric oxide (FENO) concentration reliably reflects central airway inflammation, but it is not sensitive to changes in the NO dynamics in the lung periphery. By measuring FENO at several different flow rates one can estimate alveolar NO concentration (CANO), bronchial NO flux (JawNO), bronchial wall NO concentration (CawNO) and the bronchial diffusivity of NO (DawNO). Objective: We aimed t Read More
-
-
-
Fractional Exhaled Nitric Oxide and Nanomaterial Exposure in Workplaces
Authors: Ivo Iavicoli, Luca Fontana, Veruscka Leso, Maria C. Macrini and Daniela PelclovaBackground: The widespread application of engineered nanomaterials (ENMs) and the increasing likelihood of general and occupational exposure raised concerns on their possible human health impact. ENMs, in fact, may induce alterations in different organ systems, and particularly in the respiratory tract. This makes it important to identify possible biomarkers of early lung effect in exposed workers. In this regard, the possi Read More
-
-
-
Repurposing Drugs for Skin Cancer
More LessDrug repurposing is the process of developing existing or abandoned drugs for a different disease. Repurposing can circumvent higher costs and times associated with conventional drug discovery strategies because toxicity and pharmacokinetics profiles are typically already established. This brief review focuses on efforts to repurpose drugs for skin cancer and includes reuse of antihypertensives, anthelmintics and antifungals Read More
-
-
-
Drugs Repurposing in High-Grade Serous Ovarian Cancer
Authors: Manuel Torralba, Rossella Farra, Marianna Maddaloni, Mario Grassi, Barbara Dapas and Gabriele GrassiBackground: Ovary Carcinoma (OC) is the most lethal gynecological neoplasm due to the late diagnoses and to the common development of resistance to platinum-based chemotherapy. Thus, novel therapeutic approaches are urgently required. In this regard, the strategy of drug repurposing is becoming attractive. By this approach, the effectiveness of a drug originally developed for another indication is tested in Read More
-
-
-
Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy
Nanodrugs represent novel solutions to reshuffle repurposed drugs for cancer therapy. They might offer different therapeutic options by combining targeted drug delivery and imaging in unique platforms. Such nanomaterials are deemed to overcome the limitations of currently available treatments, ultimately improving patients’ life quality. However, despite these promises being made for over three decades, the poor cli Read More
-
-
-
Novel Aspects of Insulin-like Growth Factor 1/insulin Network in Chronic Inflammatory Airway Disease
Authors: Wenjing Ruan, Jing Deng and Kejing YingAt least a proportion of patients suffering from chronic inflammatory airway diseases respond poorly to the bronchodilator and corticosteroid therapies. There is a need for the development of improved anti-inflammatory treatment. Insulin Growth Factor 1 (IGF1) and insulin participate in not only metabolism and glucose homeostasis, but also many other physiological and pathophysiological processes, including growth an Read More
-
-
-
Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy
Authors: Yong Ling, Ji Liu, Jianqiang Qian, Chi Meng, Jing Guo, Weijie Gao, Biao Xiong, Changchun Ling and Yanan ZhangProtein Kinase Inhibitors (PKIs) and Histone Deacetylase Inhibitors (HDACIs) are two important classes of anticancer agents and have provided a variety of small molecule drugs for the treatment of various types of human cancers. However, malignant tumors are of a multifactorial nature that can hardly be “cured” by targeting a single target, and treatment of cancers hence requires modulation of multiple biological targe Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
